Renal Cell Carcinoma : Understanding the Most Common Kidney Cancer

Introduction

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer in adults, comprising about 85–90% of all primary renal malignancies. It arises from the epithelial cells of the proximal renal tubules. RCC is notorious for being asymptomatic in early stages, earning its reputation as a “silent killer.” However, advancements in imaging techniques, molecular diagnostics, and targeted therapy have significantly improved detection and outcomes.

Incidence and Epidemiology

Renal Cell Carcinoma (RCC) accounts for about 2–3% of all adult cancers globally.
It is more commonly diagnosed in males than females, with a ratio of approximately 2:1.
Peak incidence occurs between 60 and 70 years of age.
The incidence has been increasing worldwide, partly due to widespread use of imaging modalities.
Higher rates are seen in North America and Europe compared to Asia and Africa.

Risk Factors

Modifiable Risk Factors:

Smoking (doubles the risk)
Obesity (especially in postmenopausal women)
Hypertension
Chronic analgesic abuse (especially phenacetin)
Occupational exposures (cadmium, asbestos, trichloroethylene)

Non-Modifiable Risk Factors:

Family history of Renal Cell Carcinoma (RCC)
Chronic kidney disease and dialysis
Genetic predisposition (e.g., von Hippel–Lindau disease, Birt–Hogg–Dubé syndrome, HLRCC)

Pathology and Subtypes

Renal Cell Carcinoma includes several subtypes:

Clear Cell RCC (ccRCC) – ~75–80%
- Associated with VHL gene mutation
- Characterized by lipid- and glycogen-rich cells
Papillary RCC (Type 1 and 2) – ~10–15%
- Type 1 is less aggressive; Type 2 has worse prognosis
Chromophobe RCC – ~5%
- Generally has better prognosis
Collecting duct carcinoma and Medullary carcinoma – Rare but very aggressive

Clinical Presentation

Often asymptomatic in early stages and detected incidentally. Classical triad (rare):

Hematuria (gross or microscopic)
Flank pain
Palpable abdominal mass

Other signs and symptoms:

Fatigue
Weight loss
Fever without infection
Varicocele (left-sided due to renal vein obstruction)
Hypertension
Polycythemia (due to ectopic erythropoietin)
Hypercalcemia (due to PTHrP production)
Metastatic symptoms: bone pain, cough, dyspnea

Diagnosis

Imaging:

Ultrasound: Often first test in hematuria workup
CT abdomen with contrast: Gold standard for diagnosis and staging
MRI: Preferred in patients with contrast allergy or impaired kidney function
Chest X-ray or CT thorax: For metastasis evaluation
Laboratory tests:

CBC: May show anemia or polycythemia
Renal function tests
Liver function tests (Stauffer’s syndrome)
Serum calcium and LDH
Urinalysis: May show microscopic hematuria
Biopsy:

Not routinely done for resectable masses
Used in metastatic or unresectable cases to guide systemic therapy

Staging (TNM Classification)

Stage I: Tumor ≤7 cm, confined to kidney
Stage II: Tumor >7 cm, still confined to kidney
Stage III: Spread to major veins or adrenal gland
Stage IV: Distant metastasis or regional lymph node involvement

Treatment

Localized RCC (Stages I–III)

Surgical Options:
- Radical nephrectomy: Complete removal of the kidney and surrounding structures
- Partial nephrectomy: Nephron-sparing surgery, preferred for tumors <4 cm or in solitary kidney
Ablative therapies: Cryoablation or radiofrequency ablation in non-surgical candidates
Active surveillance: For small tumors (<3 cm) in elderly or comorbid patients

Metastatic RCC (Stage IV)

Targeted therapy:
- VEGF inhibitors: Sunitinib, axitinib, pazopanib
- mTOR inhibitors: Everolimus, temsirolimus
Immunotherapy:
- Checkpoint inhibitors: Nivolumab, pembrolizumab, ipilimumab
- Combination regimens: e.g., nivolumab + ipilimumab or pembrolizumab + axitinib
Cytoreductive nephrectomy: Beneficial in select metastatic cases
Radiation and palliative care: For bone and brain metastases

Lifestyle and Prevention

Quit smoking
Maintain a healthy BMI
Control blood pressure
Avoid unnecessary analgesics
Regular screening for high-risk individuals (genetic predisposition, family history)

Prognosis

5-Year Survival Rates (Based on Stage):
- Localized (Stage I): ~93%
- Regional (Stage II–III): ~69%
- Distant metastases (Stage IV): ~13%
Prognostic factors:
- Stage and grade
- Performance status
- Time to metastasis
- Laboratory markers (calcium, LDH, hemoglobin)

Recent Research and Advancements

Genomic Profiling: Use of next-generation sequencing to identify targetable mutations
Newer Immunotherapy Combinations: Dual checkpoint blockade and combinations with TKIs show improved progression-free survival
Liquid Biopsies: Non-invasive detection and monitoring of circulating tumor DNA
Artificial Intelligence in Imaging: AI tools to improve early detection and precision in staging
Neoadjuvant and Adjuvant Therapies: Trials evaluating systemic treatment before and after surgery for better outcomes

Follow-Up and Surveillance

First 3 years: Imaging every 6 months
After 3–5 years: Annually, based on recurrence risk
Monitor renal function, blood pressure, and for signs of recurrence or metastasis

Frequently Asked Questions (FAQs)

1. What are early signs of Renal Cell Carcinoma (RCC) ? Most cases are asymptomatic early. Hematuria or incidental findings on imaging are often the first clues.

2. Is Renal Cell Carcinoma (RCC) curable? Yes, if diagnosed early and localized, it is often curable with surgery.

3. How is RCC different from other kidney cancers? RCC arises from the renal tubules and is more resistant to chemotherapy compared to other types like transitional cell carcinoma.

4. Can kidney cancer spread to other organs? Yes, common sites include lungs, bones, liver, and brain.

5. Does Renal Cell Carcinoma (RCC) run in families? Hereditary forms exist, such as VHL syndrome. Genetic counseling is recommended for those with a strong family history.

6. Can lifestyle changes prevent Renal Cell Carcinoma (RCC) ? Yes. Avoiding smoking, managing weight and blood pressure, and limiting harmful chemical exposures can reduce risk.

7. What is the role of immunotherapy in Renal Cell Carcinoma ? It has revolutionized treatment for metastatic RCC, significantly improving survival in advanced stages.

8. Are there any blood tests to detect RCC? No specific blood test exists for early detection, but labs can help in diagnosis and prognosis.

9. What is the life expectancy after Renal Cell Carcinoma (RCC) diagnosis? Depends on the stage. Localized disease has excellent prognosis; metastatic cases vary widely with treatment response.

10. Is dialysis needed after kidney removal? Not if the remaining kidney functions normally. Dialysis may be needed in those with poor residual function or both kidneys affected.

Conclusion

Renal Cell Carcinoma is a significant health concern with increasing global incidence. Despite being potentially silent in early stages, advancements in imaging, surgical techniques, targeted therapy, and immunotherapy have transformed its management. Continued research and awareness can further improve early detection, personalized treatment, and survival outcomes. Regular follow-up and patient education remain crucial pillars in managing RCC effectively.

For more updates, follow us on X (Twitter), Instagram & Facebook. And our website MED COLLEGE DARSHAN.